Advances in Cancer Immunotherapy (ACI) Committee

 View Only
last person joined: one year ago 

The Advances in Cancer Immunotherapy™ (ACI) Committee oversees the planning and implementation of SITC’s regional introductory, CME-, CNE-, CPE- and MOC-certified programs created for the entire clinical cancer care team. The committee provides expert guidance to the appropriate audiences and timely content relevant to advancing patient care using FDA-approved immunotherapies.
Log in to see this information

Either the content you're seeking doesn't exist or it requires proper authentication before viewing.